ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / FEMY / dividends
ICU (31) PLSM (47) SINT (33) CNSY (25) ⌘ Pro Terminal →

Femasys Inc. (FEMY) Dividend Safety Gauge & 10-Year DRIP Compounder

$1.37 +1.11% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.37

Femasys Inc. (FEMY) carries a Roarable Rating of E (Strong Sell) with 30/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $11.5M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on FEMY Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is FEMY stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Femasys Inc. (NASDAQ: FEMY) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $1.37 (+1.11% 1D, market cap $11.5M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, FEMY ranks #811 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does FEMY compare to ICU and PLSM in the Health Care sector?
▼

Within the Health Care sector (Medical/Dental Instruments), FEMY carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of 62.0%, and ROIC of -35.0%. By comparison, ICU (SeaStar Medical Holding Corporation) holds a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $11.8M) and PLSM (Pulsenmore Ltd.) posts a D grade (47/100 RQD, P/E N/A, ROIC —, cap $10.9M). Among the 5-stock peer group, FEMY leads on earnings multiple (N/A) while FEMY leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for FEMY?
▼

Per FEMY's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001339005), Femasys Inc. generated $2.3M in revenue (+40.8% YoY), -$18.6M in net income, and -$19.2M in free cash flow against $20.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $1.37 (+0.01%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (30/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.6% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510030
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Cash (6)Whales (3)SEC (10)Macro (6)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-12.4% Base Target
$23 Bull$1 Base$1 Bear
📬 FREE FEMY RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for FEMY)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (30/100 Composite)
🔍 WHY FEMY SCORES 30/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (33% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9

▲ #2 Bullish Driver: Cash Engine Quality+6/20 pts (20% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 62% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
38
Grade E$1.76-5.1% Next Q
Q2 (-2Q)
35
Grade E$1.67-18% Next Q
Q3 (-1Q)
33
Grade E$1.37+0% Next Q
Current
30
Grade E$1.37-9.6% Hist 90D α
Trajectory: E (38) → E (30)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a FEMY Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While FEMY currently carries a cautious 30/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.22) and Max Pain ($1.44) forces dealer call-delta covering toward $23.31.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $FEMY• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “FEMY Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 30%NO 70%Trade / Inspect Odds →
CASH DIVIDEND + BUYBACK YIELD
1.8% Total Yield
0% Cash ($0.00/yr) + 1.8% Buybacks
PAYOUT SAFETY SPEEDOMETER
74/100 • REINVESTING IN GROWTH + BUYBACKS
FREE CASH FLOW PAYOUT RATIO
0% (100% Reinvested)
Retains cash flow for R&D and share repurchases
INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (16.3% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $45,269

Est. Year-10 Shareholder Yield: $815/yr
$11.6K
Yr 1
$13.5K
Yr 2
$15.7K
Yr 3
$18.3K
Yr 4
$21.3K
Yr 5
$24.7K
Yr 6
$28.8K
Yr 7
$33.5K
Yr 8
$38.9K
Yr 9
$45.3K
Yr 10
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring FEMY)

  • ✓Walkthrough of FEMY's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
FEMY // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -81.59%⚡ TESTING RESISTANCE
2026-11-03O $1.35H $1.37L $1.35C $1.37VOL 95.1K
RES: $1.94SUP: $1.27SMA50: $2.22SMA200: $6.02
$12.98$9.82$6.65$3.48$0.32RES $1.94SUP $1.27$1.372026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

FEMY Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 FEMY Butterfly Map → + Track FEMY →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +40.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on FEMY today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for FEMY. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for FEMY today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (FEMY)

Health Care Rank #811 of 1015 ⚔️ ICU vs FEMY Full Matrix →

1. Head-to-Head Health Care Peer Comparison (FEMY vs. ICU, PLSM, SINT, CNSY)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Femasys Inc. (FEMY) ranks #811 by composite RQD confidence (30/100, grade E) and #879 by equity capitalization ($11.5M). Within this direct 5-issuer industry benchmark cohort, FEMY leads on earnings valuation at N/A trailing P/E, while FEMY leads on capital efficiency and profitability with -35.0% ROIC and 62.0% gross margin. PLSM currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with FEMY at 30/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
FEMY ACTIVE
Femasys Inc.
E 30/100 — 62.0% -35.0% +1.11% $11.5M Benchmark Subject
ICU
SeaStar Medical Holding Corporation
E 31/100 — 95.7% -35.0% -3.03% $11.8M /icu-vs-femy →
PLSM
Pulsenmore Ltd.
D 47/100 — — — +3.09% $10.9M /plsm-vs-femy →
SINT
SiNtx Technologies Inc.
E 33/100 — 45.3% -35.0% -1.16% $12.8M /sint-vs-femy →
CNSY
Cerenome Inc.
E 25/100 — — -35.0% -2.30% $12.9M /cnsy-vs-femy →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001339005 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Femasys Inc. (FEMY) reported GAAP revenue of $2.3M (+40.8% vs. FY2024 revenue of $1.6M , and +113.9% cumulative change since FY2023) , GAAP net income of -$18.6M, operating cash flow of -$18.7M, and free cash flow of -$19.2M (+4.9% YoY). On the balance sheet, FEMY closed FY2025 with $20.7M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $2.3M -$18.6M -$18.7M -$19.2M $20.7M —
FY2024 (FY) 2024-12-31 $1.6M -$18.8M -$19.4M -$20.2M $12.4M —
FY2023 (FY) 2023-12-31 $1.1M -$14.2M -$11.3M -$11.3M — —

3. FEMY Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is FEMY stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Femasys Inc. (NASDAQ: FEMY) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $1.37 (+1.11% 1D, market cap $11.5M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, FEMY ranks #811 in composite RQD confidence.

How does FEMY compare to ICU and PLSM in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), FEMY carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of 62.0%, and ROIC of -35.0%. By comparison, ICU (SeaStar Medical Holding Corporation) holds a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $11.8M) and PLSM (Pulsenmore Ltd.) posts a D grade (47/100 RQD, P/E N/A, ROIC —, cap $10.9M). Among the 5-stock peer group, FEMY leads on earnings multiple (N/A) while FEMY leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for FEMY?

Per FEMY's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001339005), Femasys Inc. generated $2.3M in revenue (+40.8% YoY), -$18.6M in net income, and -$19.2M in free cash flow against $20.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is FEMY trading relative to its 50-day, 200-day, and 52-week technical levels?

FEMY last traded at $1.37 (+1.11% on volume of 95,122 shares), positioning the stock -38.29% below its 50-day simple moving average ($2.22) and -77.24% below its 200-day simple moving average ($6.02). Across its 52-week range of $1.30 to $22.20, FEMY sits at the 0.3% percentile with a 14-day RSI of 28.0 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.20 to $1.54).

Direct Sub-Reports: FEMY RQD Cockpit FEMY 12M Forecast FEMY Earnings & Move FEMY Dividends & DRIP FEMY Insiders & 13F FEMY Whale Options FEMY Profit Sankey FEMY News & Why
ROARABLE RATING BRIEF • RQD 30/100 (E) ✓ SEC XBRL & RQD VERIFIED

FEMY — Femasys Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Femasys Inc. (FEMY) earns a live Roarable RQD composite score of 30/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $1.37 (+1.11% 1D, market capitalization $11.5M).

  • Fundamental Cash Engine (6/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 62.0%, operating margin of -60.0%, and free cash flow yield of —.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (6/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 4/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Femasys Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Medical/Dental Instruments industry. It operates with a market capitalization of $0.0B, though the market data section reports $11.3M. Per the recent news feed, one catalyst references a new pharmacy partnership offering medication coordination and preferred pricing to fertility patients, which suggests a fertility-focused customer base. Revenue was $2.3M in FY 2025, with a reported gross margin of 62%.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Femasys Inc. (FEMY) reported $2.3M in annual revenue (up from $1.6M in FY2024, +40.8% YoY) and -$18.6M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($1.1M revenue, -$14.2M net income) through FY2025, FEMY scaled operating cash flow to -$18.7M and free cash flow to -$19.2M, backed by $20.7M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 30/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 6/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $1.30 – $22.20 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream suppliers and downstream customers are — Sector correlations beyond the Health Care and Medical/Dental Instruments classification are — Investors should note that the absence of mapped links means no second-order ripples can be traced from this source, and that the company's own catalyst set (fertility-focused pharmacy partnership and sales-force execution) would be the primary channel through which operational changes propagate.

  • Key Question #1: Can FEMY sustain or expand its -60.0% operating margin and -35.0% ROIC against Medical/Dental Instruments peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $2.3M and free cash flow of -$19.2M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is FEMY's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

FEMY Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Femasys Inc. (FEMY) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to FEMY Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

FEMY Bull vs. Bear Conversation Board — What's Your Call at $1.37?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON FEMY 🐻 33% BEARISH CONVICTION
1. Pick Your Side on FEMY:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
DE DeepValue_CFA RQD DEBATE OPENER • Institutional Buy-Side 🐂 BULLISH 🎯 Target: $1.74 (+27.0%)
📌 Pinned Debate

Cash rose to $9.3M in FY 2025 from $3.5M in FY 2024 while revenue grew from $1.1M in FY 2023 to $2.3M in FY 2025, and the forensic bala

Cash rose to $9.3M in FY 2025 from $3.5M in FY 2024 while revenue grew from $1.1M in FY 2023 to $2.3M in FY 2025, and the forensic balance sheet pillar scored 10/20 with Altman Z of 2.5.. When you look under the hood at FEMY, Fundamental Cash Engine is 6/20 with 62.0% gross margins and -35.0% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (3/20) has been quietly accumulating below $22.20. My 12M target is $1.74.

VolSurface_Trader 🐂 BULL

@RedlineAuditor Shorting a 3/20 institutional whale-flow stock at $1.37 is dangerous when funds are rotating into Health Care.

RE RedlineAuditor RQD DEBATE OPENER • Accounting Quality Watch 🐻 BEARISH 🎯 Target: $1.10 (-19.7%)
Spot @ $1.37

FCF was -$19.2M in FY 2025, ROIC is -35%, and the RQD rating is 30 with an E grade labeled Strong Sell — Forensic Risk / Avoid.

Careful chasing FEMY at $1.37. FCF was -$19.2M in FY 2025, ROIC is -35%, and the RQD rating is 30 with an E grade labeled Strong Sell — Forensic Risk / Avoid.. Gross margin is 62.0%, but operating margin is -60.0%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $1.10 on multiple compression.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.35 -5.42% GLD $361.65 -3.59%